Trial Profile
A Randomized, Placebo-Controlled, Double-Blind Study of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine to Investigate the Safety, and Efficacy in Chinese 20 - to 45-Years-Old Women.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Adenocarcinoma; Cervical cancer; Cervical intraepithelial neoplasia; Female genital diseases; Human papillomavirus infections
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Merck & Co; Merck Sharp & Dohme
- 09 Jan 2019 Results assessing safety of quadrivalent human papillomavirus (qHPV) vaccine in chinese women published in the Vaccine
- 16 Aug 2018 Primary endpoint (Entire Study: Combined Incidence of CIN2+ Related to HPV Types 16 or 18 in 20 to 45 Year Old Participants (End of Study Test of Hypothesis)) has not been met.
- 16 Aug 2018 Results published in the Vaccine.